Evogene
EVGN
23 hedge funds and large institutions have $28.2M invested in Evogene in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0.01% more ownership
Funds ownership: 3.52% → 3.53% (+0.01%)
4% less funds holding
Funds holding: 24 → 23 (-1)
8% less capital invested
Capital invested by funds: $30.6M → $28.2M (-$2.42M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$722K |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$217K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$147K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$48.6K |
| 5 |
JP Morgan Chase
New York
|
+$35.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$722K |
| 2 |
Morgan Stanley
New York
|
-$405K |
| 3 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$14.4K |
EVGN Hedge Fund Activity: Q3 2018 in Review
23 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2018, worth a combined $28.2M — down 7.9% from $30.6M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of EVGN and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 9 added.
The largest buyer was Goldman Sachs, adding an estimated $722K. The largest seller was Canada Pension Plan Investment Board, cutting an estimated $722K.
- 23 institutional investors held Evogene (EVGN) as of Q3 2018, down from 24 in Q2 2018.
- Funds reported $28.2M of Evogene stock for Q3 2018, down 7.9% quarter-over-quarter.
- 0 funds opened new Evogene positions in Q3 2018 and 1 closed out, a net change of -1 holder.
- The largest Evogene buyer in Q3 2018 was Goldman Sachs, an estimated $722K added.
- The largest Evogene seller in Q3 2018 was Canada Pension Plan Investment Board, an estimated $722K sold.
Based on aggregated 13F filings for Q3 2018.